Oversold, OCGN is gaining momentum. According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN...
Continue reading >>The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...
Continue reading >>...
Continue reading >>The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...
Continue reading >>...
Continue reading >>The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...
Continue reading >>